Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Weycker
Derek
D
Barron
Richard L
RL
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects*; D006760:Hospitalization; D006801:Humans; D007239:Infections / Q000628:therapy*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced* / Q000150:complications*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012107:Research Design; D012306:Risk
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim